B-type natriuretic peptide levels and volume status in twice-weekly hemodialysis patients

Fang, Nina; Che, Miaolin; Shi, Ling; Yu, Zanzhe; Ni, Zhaohui; Fang, Wei; Pang, Huihua; Gu, Leyi; Lin, Xinghui

doi:10.1080/0886022x.2021.1971091

Cited by 6 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a recent study, serum BNP levels were investigated according to the volume status of hemodialysis patients, and a significant decrease was found in serum BNP levels in patients who received hemodialysis three times per week compared to those who received treatment two times per week [27]. The study's authors report that the volume status was worse in those who received dialysis twice weekly and that BNP levels were a strong predictor of mortality in hemodialysis patients.…”

Section: Discussionmentioning

confidence: 99%

Assessment of BNP and BDNF results in elective endovascular cerebral aneurysm treatment

Sukun

Çekiç

2021

Ir J Med Sci

View full text Add to dashboard Cite

Background B-type natriuretic peptide (BNP) levels increase with an increase in intracranial pressure. A decrease in BNP levels has been found to be associated with patient positive prognosis. Brain-derived neurotrophic factor (BDNF) levels decrease in patients with acute stroke. Aims To compare the BNP and BDNF values in serum before and after elective endovascular cerebral aneurysm treatment (ECAT). Methods A total of 50 patients who underwent elective ECAT were included in the study. Exclusion criteria were determined to be history of heart failure or heart attack (n = 8), renal failure (n = 5), subarachnoid hemorrhage (n = 4), or previous aneurysm clip procedure (n = 3). Intravenous blood samples were obtained from 30 patients who underwent elective ECAT before and after treatment. After centrifugation, the BNP and BDNF values in serum were obtained with the ELISA method and compared. Results This study included 19 female and 11 male patients, aged between 24 and 75 years. The average age of the patients was 51.27 ± 13.31 years. The median BDNF values did not change significantly after ECAT (before the endovascular procedure: 3.1 ± 1.3 pg/dl; after the endovascular procedure: 2.8 ± 0.9 pg/dl, p = 0.16). Median BNP levels decreased significantly after ECAT (before the endovascular procedure: 617.50 ± 483.11 pg/ml; after the endovascular procedure: 395.00 ± 352.15 pg/ml, p < 0.001). Conclusions After elective endovascular cerebral aneurysm treatment, the BNP values in serum decreased significantly, and the BDNF values in serum did not change significantly. Keywords BDNF • BNP • Cerebral aneurysm • Endovascular treatment Abbreviations BNPB-type natriuretic peptide BDNF Brain-derived neurotrophic factor ECAT Endovascular cerebral aneurysm treatment

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of BNP and BDNF results in elective endovascular cerebral aneurysm treatment

Sukun

Çekiç

2021

Ir J Med Sci

View full text Add to dashboard Cite

show abstract

“…As interest in this field has increased, several clinical trials have been performed to further evaluate outcomes in patients undergoing incremental dialysis ( Table 2 ). 2 , 5 , 28 , 34 , 36–50 Preservation of RKF has been demonstrated in several observational cohort studies. In 2014, a cohort of 85 patients from Shanghai was evaluated where 30 patients initiated twice weekly hemodialysis for 6 months or longer, and 55 patients were started and maintained on thrice weekly hemodialysis treatment.…”

Section: Outcomes Datamentioning

confidence: 94%

“…B-type natriuretic peptide levels were a predictor of mortality in this study, and patients with B-type natriuretic peptide > 500 pg/mL had significantly worse survival compared to those with lower values. 28 …”

Section: Diuretic Therapy and Volume Statusmentioning

confidence: 99%

See 1 more Smart Citation

Incremental Hemodialysis: What We Know so Far

Soi¹,

Faber²,

Paul³

2022

IJNRD

View full text Add to dashboard Cite

Traditionally, patients that develop progressive chronic kidney disease in need of kidney replacement therapy are prescribed thrice weekly in-center hemodialysis sessions at the beginning of therapy. This empiric prescription is based on historic trials that were comprised of mostly prevalent patients. Incremental hemodialysis is the process of performing <3 sessions of dialysis per week or limiting dialysis dose by duration at the initial onset of treatment to provide a more gradual transition, mimicking the progressive nature of kidney disease. Adding clearance contributions from residual kidney function is the standard of care with peritoneal dialysis but has not routinely been employed with hemodialysis. Accounting for residual kidney function accompanied by improvement in adjuvant pharmacotherapy, such as newer potassium binding agents and dietary modification, can augment dialytic clearances and allow for an incremental approach. Utilizing incremental dialysis has been associated with both preserving residual kidney function as well as improving patient quality of life. Barriers to this approach include concerns regarding patient acceptance of dialysis prescription changes, adherence to therapy, and provider factors that would require a restructuring of the current thrice weekly hemodialysis rubric. Candidacy for incremental therapy has shown the best outcomes when urea clearances exceed 3 mL/min and urine volumes are >500 mL/day, although these measures have been deemed conservative. A significant amount of retrospective and registry data has been supportive of initiating incremental hemodialysis and several pilot studies have shown the feasibility of implementing such an approach. Larger, randomized control trials are needed to fully evaluate safety and efficacy to allow for more widespread acceptance of this patient-centered approach to chronic kidney disease.

show abstract

“…Variation of BNP may re ect volume load and simultaneously evaluate cardiac function, which may be a more relevant predictor for patient outcome. However, previous studies provided inconsistent threshold of BNP in hemodialysis patients, and were lack observation for prognosis [14,15]. In this study, we used blood pressure and BIS methods to de ne the normal volume status of hemodialysis patients, analyzed the relatively normal distribution of BNP expression, and explored the relationship between the shift in BNP levels and prognosis of hemodialysis patients.…”

Section: Introductionmentioning

confidence: 99%

Brain natriuretic peptide reflects volume status and influences on survival of hemodialysis patients

Wang

Chen

2022

Preprint

View full text Add to dashboard Cite

Background Periodic volume accumulation is a characteristic feature of hemodialysis. Aim of the study was to investigate the relatively normal range of brain natriuretic peptide (BNP) in hemodialysis patients and to explore its role in volume management. Methods Patients on hemodialysis were enrolled. Normal range of BNP was deduced from patients with normal volume status defined by systolic blood pressure (SBP) and over hydration (OH). Hemodialysis patients were classified according to BNP expression at baseline and followed-up for 57 months. The outcome was defined as all-cause mortality, and cardiovascular disease related death. Results Pre-dialysis BNP and BCM measurement was conducted in 127 hemodialysis patients. BNP significantly correlated with OH in total patients (r = 0.255, P = 0.004). In patients with appropriate volume load, the average of BNP was 701 (± 645)pg/ml, with the 95% confidence interval (CI) of 500 ~ 902pg/ml. In patients with BNP < 902pg/ml, SBP significantly correlated with OH. Patients with BNP ≥ 902/ml showed increased risk of all-cause mortality (HR = 3.151, P < 0.001) and cardiovascular mortality (HR = 7.381, P < 0.001). Reduced BNP expression during the first year after baseline resulted in significantly decreased all-cause mortality. Conclusion Pre-dialysis measured BNP levels are associated with volume status, and normal range is from 500 to 902pg/ml. Patients with upregulated BNP expression showed increased risk of all-cause mortality and cardiovascular death. To reduce BNP expression to normal range showed protective effect on all-cause and cardiovascular mortality in long-term observation.

show abstract

B-type natriuretic peptide levels and volume status in twice-weekly hemodialysis patients

Cited by 6 publications

References 31 publications

Assessment of BNP and BDNF results in elective endovascular cerebral aneurysm treatment

Assessment of BNP and BDNF results in elective endovascular cerebral aneurysm treatment

Incremental Hemodialysis: What We Know so Far

Brain natriuretic peptide reflects volume status and influences on survival of hemodialysis patients

Contact Info

Product

Resources

About